AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05681065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TeNDER tool
Description: The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor.
Study NCT05159518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion
Study NCT06197789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-105
Description: Subjects will be administered with autologous fibroblasts through injection
Study NCT06197789 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with Placebo through injection
Study NCT04751318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg Test Drug Enteric Coated Granules
Description: Investigational Medicinal Product
Study NCT04751318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg Reference Product Enteric Coated Granules
Description: Cymbalta (Eli Lilly)
Study NCT03570814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Albendazole on Day 1
Description: Participants will receive Albendazole 400mg on study day 1.
Study NCT03570814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Albendazole on Day 1
Description: Participants will receive Albendazole 400mg on study day 1.
Study NCT03570814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Ivermectin on Day 1
Description: Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
Study NCT03570814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Ivermectin on Day 1
Description: Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
Study NCT03570814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Azithromycin on Day 1
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
Study NCT03570814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Azithromycin on Day 15
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
Study NCT04555564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technicium 99 MAA infusion
Description: 4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
Study NCT04966260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Virtual Reality
Description: This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
Study NCT04966260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.
Study NCT04966260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Virtual Reality
Description: This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
Study NCT05549830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Positioning
Description: In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals.
Study NCT04593758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613 + Hydroxychloroquine
Description: dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.~Starting dose of 80% of the maximum tolerated (MTD) identified in patients ≥ 45 kg for patients \< 45 kg
Study NCT04950530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
Study NCT05488457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deuterated oxytocin (d5OT)
Description: Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
Study NCT04770116 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auditory Stimulation
Description: The device records biosignals and precisely plays tones to enhance sleep slow waves.
Study NCT04770116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation
Description: The device records biosignals and precisely plays tones to enhance sleep slow waves.
Study NCT05833438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN+AZA-5
Description: Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
Study NCT04914533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminance RED Low Level Laser Therapy Device
Description: Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
Study NCT06259669 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib Cream
Description: Ruxolitinib Cream
Study NCT03120130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort
Study NCT05367791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: POSTUR
Description: Training sessions without any stimulation
Study NCT05367791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Localised Vibration
Description: Training sessions with localized vibration
Study NCT05367791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Somatosensory Electrical Stimulation
Description: Training sessions with somatosensory electrical stimulation
Study NCT05743361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
Study NCT04861935 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound evaluation
Description: ultrasound evaluation of normal patients and patients who have a sacral dimple
Study NCT04861935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound evaluation
Description: ultrasound evaluation of normal patients and patients who have a sacral dimple
Study NCT04951609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally.
Study NCT05910619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurolith Transcranial Pulse Stimulation Active
Description: 5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume \~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
Study NCT05910619 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurolith Transcranial Pulse Stimulation Sham
Description: The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
Study NCT06165328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT and colonoscopy
Description: All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
Study NCT05440734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 2 Mg Oral Tablet, slow release
Study NCT04754594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection
Study NCT04754594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study NCT05440734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill identical to the treatment pill
Study NCT06106802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg/day
Study NCT06106802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib 500mg/day
Study NCT06345625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognition
Description: 1. The CatchU® app quantitatively and objectively measures the ability to integrate visual-somatosensory information using reaction time test data.~2. Digit Symbol Substitution test assesses processing speed and attention by requiring individuals to match symbols with corresponding numbers within a specified time frame.~3. Trail Making Test part 1 and 2: assesses cognitive flexibility, visual attention, and task-switching by having individuals connect numbered circles in sequence (part 1) and then alternate between numbers and letters (Part 2).~4. Go/No Go test measures an individual's ability to inhibit a prepotent response (No-Go) and execute a response when required (Go). This test provides insights into executive functioning, particularly inhibitory control.
Study NCT06345625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory function
Description: 1. Cervical Sensorimotor control will be measured through a wireless wearable sensor 3D-cervical trainer by Sensamove on the placed on the head of the participant. The 3DCT registers cervical position sense by the Head Repositioning Accuracy test where the subject must relocate the head to the previously memorized (neutral) head position with the eyes closed and the joint position error degrees are registered. Cervical movement sense is examined using 'The Fly'-test where the subject ought to follow a movement pattern displayed on the screen in front of them. The movement of the neck-head unit is there upon tracked by the 3DCT and projected on the screen.~2. Vestibular function will be assessed through 3D-video Head Impulse Testing (vHIT), examining the state of the three semicircular canals by delivering the vestibulo-ocular reflex (vor) gain and vor gain asymmetry.~3. For the assessment of static and dynamic visual acuity, functional Head Impulse Testing (fHIT) will be used.
Study NCT06345625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty
Description: Frailty will be assessed using the Fried criteria, comprising 5 categories (each accounting for 1 point if scored positive): Unintentional weight loss (interview), weakness (grip strength with hand-held dynamometer), poor endurance and energy (two statements of the CES-D Depression Scale), slowness (walking speed over 15ft through gait analysis) and low physical activity level (Minnesota Leisure Time Activity questionnaire)(Fried et al., 2001).
Study NCT06345625 — intervention group
Intervention type: OTHER
Intervention: Biomechanical movement analysis
Description: Markers will be placed on the predefined anatomical locations and surface electrodes for electromyography will be applied at the predefined muscle locations following the SENIAM-guidelines. The Microsoft HoloLens 2 is fixated on the participant's head which will, on one hand, provide the cue to the participant for the head movement and on the other hand track eye and head movements. A safety harness is attached to the body and the ceiling of the lab. At the start of the trial, the subject will see a projection by the HoloLens 2 on the real environment moving to the left; right; upward; downward (cue in randomized order) which the participant is ought to follow with eyes and head. First while standing still and second while walking the 10-meter overground walkway at a self-preferred walking speed.
Study NCT06345625 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: The researcher will visit the possible participants (at their home, community centre, etc.) and after written consent on screening procedure is provided, the tests for eligibility will be performed.~1. Interview: asking about age (years), gender (male/female), medical history and the number of falls in the last 12 months .~2. Timed Up-and-Go (TUG) to check walking ability. TUG is a sensitive and specific measure for identifying risk for falls (Shumway-Cook et al., 2000).
Study NCT06345625 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: Participants are followed up for 12 months. They fill in a fall diary and telephone reminders will be performed monthly to encourage participants to complete and return their diaries.
Study NCT05697562 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rubber band ligatures (RBL)
Description: This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
Study NCT05697562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Rectal Artery Embolization (SRAE)
Description: This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks.
Study NCT05697562 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)
Description: The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
Study NCT05859529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: The drug was administered by a single subcutaneous injection
Study NCT04772534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study NCT06615245 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No VR vs. immersive high tech VR
Description: No VR vs. immersive High Tech VR
Study NCT06615245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plausible control vs immersive High Tech VR
Description: plausible control condition vs. immersive high tech VR
Study NCT05289596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUT-i)
Description: SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
Study NCT05358275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical cutting guide with piezo
Description: 3D planned lid surgery
Study NCT04572737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity plan to break up sitting time
Description: This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
Study NCT05031975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 100 mg/smq intravenous infusion every 14 days
Study NCT05031975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
Study NCT05450900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriogonadotropin Alpha
Description: drug, active
Study NCT05450900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Choriogonadotropin Alpha
Description: drug, active
Study NCT05450900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: biotin
Description: supplement, oral
Study NCT05450900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcellulose filler
Description: supplement, oral
Study NCT04480554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
Study NCT04480554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
Study NCT04480554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-Naltrexone
Description: Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
Study NCT04893915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced memory-like NK cells
Description: Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
Study NCT05053633 — intervention group
Intervention type: PROCEDURE
Intervention: Combined spinal epidural anesthesia
Description: The Anxiety (Visual Analogue Scale for Anxiety), pain (Visual Analogue Scale), and the Analgesia Nociception Index (ANI) assessments are conducted at four specific time points: lateral position, local anesthesia, epidural needle puncture and 2 minutes after puncture.